2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
This guideline cites 19 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2023
- Source
- Virani SS, Newby LK, et al. Circulation. 2023;148(9):e9–e119.doi 10.1161/CIR.0000000000001168
The US counterpart to the ESC's chronic coronary syndrome guideline, published a year earlier and drawing sharper conclusions in two places. Beta-blockers: routine long-term beta-blockade after myocardial infarction is dropped unless LVEF is ≤40% (or there is another indication) — the ESC 2024 CCS document is more permissive. Cardiometabolic therapy: SGLT2 inhibitors and GLP-1 receptor agonists are recommended in chronic coronary disease with type 2 diabetes, and low-dose colchicine gets a 2b for residual inflammatory risk. On revascularisation both societies land in the same place after ISCHEMIA — it relieves angina, it does not prolong life in stable disease with preserved ejection fraction. The register's trials are grouped by theme below.
Revascularisation vs. medical therapy8
- 2022REVIVED-BCIS2Cardiology · Coronary · PCI vs OMTIn 700 patients with ischaemic LV dysfunction (LVEF ≤35%) and viable myocardium, PCI plus optimal medical therapy did not reduce all-cause death or HF hospitalisation compared with optimal medical therapy alone.HR 0.9995% CI 0.78-1.27Read →
- 2020ISCHEMIA CoreCardiology · Coronary · RevascularisationIn 5,179 patients with stable CAD and moderate-to-severe ischaemia, an initial invasive strategy did not reduce CV death, MI, hospitalisation for unstable angina, HF or resuscitated arrest compared with an initial conservative strategy.HR 0.93Read →
- 2018ORBITACardiology · Coronary · RevascularisationIn 200 patients with stable single-vessel angina, PCI did not improve exercise time at 6 weeks compared with a sham procedure.Read →
- 2016STICHCardiology · HF · CABGIn 1,212 patients with ischaemic cardiomyopathy (EF ≤ 35%) and CAD, coronary-artery bypass grafting plus medical therapy reduced 10-year all-cause mortality compared with medical therapy alone.HR 0.8495% CI 0.73-0.97Read →
- 2012FAME 2Cardiology · Coronary · FFR-guided PCIIn 888 patients with stable coronary disease and a functionally significant (FFR ≤0.80) stenosis, FFR-guided PCI plus medical therapy reduced death, MI, or urgent revascularisation compared with medical therapy alone.HR 0.3295% CI 0.19-0.53Read →
- 2012FREEDOM 2012Cardiology · Coronary · PCI vs CABGIn 1,900 patients with diabetes and multivessel coronary disease, PCI with drug-eluting stents increased death, nonfatal MI, or nonfatal stroke compared with CABG.26.6% vs 18.7%Read →
- 2009SYNTAX CoreCardiology · Coronary · PCI vs CABGIn 1,800 patients with 3-vessel or left main coronary disease, PCI with paclitaxel-eluting stents increased 12-month death, stroke, MI, or repeat revascularisation compared with CABG.17.8% vs 12.4%Read →
- 2007COURAGECardiology · Coronary · RevascularisationIn 2,287 patients with stable coronary artery disease, PCI added to optimal medical therapy did not reduce death or non-fatal MI compared with optimal medical therapy alone.HR 1.05Read →
Antithrombotic therapy2
- 2019AUGUSTUS CoreCardiology · Thrombosis · AF + PCIIn 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.Read →
- 2017COMPASSCardiology · Thrombosis · Chronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.HR 0.76Read →
Lipid-lowering & anti-inflammatory therapy5
- 2019REDUCE-ITCardiology · Lipids · TriglyceridesIn 8,179 statin-treated patients with high triglycerides, icosapent ethyl reduced major adverse cardiovascular events compared with placebo.HR 0.75Read →
- 2018ODYSSEY OUTCOMESCardiology · Lipids · PCSK9 inhibitorIn 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).HR 0.8595% CI 0.78-0.93Read →
- 2017FOURIERCardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
- 2017CANTOSCardiology · Lipids · Anti-inflammatoryIn 10,061 patients with prior MI and elevated CRP, canakinumab reduced recurrent cardiovascular events compared with placebo.HR 0.8595% CI 0.74-0.98Read →
- 2015IMPROVE-ITCardiology · Lipids · Non-statin LDLIn 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.HR 0.94Read →
Cardiometabolic therapy (SGLT2i, GLP-1 RA)4
- 2019DECLARE-TIMI 58Cardiology · Cardiometabolic · SGLT2 inhibitorsIn 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.83Read →
- 2016LEADERCardiology · Cardiometabolic · GLP-1 RAIn 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.HR 0.87Read →
- 2016SUSTAIN-6Endocrinology · GLP-1 RA · CV outcome trialIn 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.HR 0.74Read →
- 2015EMPA-REG OUTCOME CoreCardiology · Cardiometabolic · SGLT2 inhibitorsIn 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.HR 0.86Read →
Published since the guideline4
- 2025REBOOTCardiology · Coronary · beta-blockerIn 8,505 patients after myocardial infarction with LVEF >40%, beta-blocker therapy did not reduce death, reinfarction, or HF hospitalisation compared with no beta-blocker.HR 1.0495% CI 0.89-1.22Read →
- 2024REDUCE-AMICardiology · Coronary · beta-blockerIn 5,020 patients after acute MI with preserved LVEF (≥50%), beta-blocker therapy did not reduce all-cause death or new MI compared with no beta-blocker.HR 0.9695% CI 0.79-1.16Read →
- 2023ORBITA-2Cardiology · Coronary · RevascularisationIn 301 patients with stable angina on no antianginal medication, PCI improved the angina symptom score compared with a placebo procedure.OR 2.21Read →
- 2023SELECT CoreCardiology · Cardiometabolic · GLP-1 RAIn 17,604 patients with obesity and cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events compared with placebo.HR 0.8Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2020LoDoCo2
Low-dose colchicine in chronic coronary disease — the basis of the 2b recommendation.
- 2019COLCOT
Colchicine after myocardial infarction.
- 2015PROMISE
Anatomical vs. functional first-line testing in suspected coronary disease.
- 2009BARI 2D
Revascularisation vs. medical therapy in type 2 diabetes.
- 2020ISCHEMIA-CKD
No benefit from an invasive strategy in advanced chronic kidney disease.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.